



09900514.811602

1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Keith D. ALLEN
Serial No.: 09/900,518
Filed: July 6, 2001
Title: Transgenic Mice Containing CX2 Gene Disruptions

Group Art Unit: 1632
Customer No. 26619
Deposit Account #. 50-1271
Docket/Order No. R-716
Date: ^{October} ~~November~~ 22, 2001

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to any action and/or consideration of the above-captioned application, please enter the following amendments.

In the Claims:

The claims previously numbered 31 through 39 have been changed so that they are consecutively numbered with the other claims, and the dependencies have been amended to match the newly numbered claims.

REMARKS

Entry of the foregoing amendment is respectfully requested. By this amendment, the claims have been amended to correct minor typographical errors (claim numbers) therein. The foregoing amendment does not introduce new matter.

Enclosed is a marked-up version of the changes made to the claims by this amendment. The enclosed pages are captioned "**Version with markings to show changes made.**" Also enclosed are replacement pages 50 and 51 with the corrections to the claims included.

Favorable action on the merits is earnestly solicited.

740 Bay Road
Redwood City, CA 94063
Tel. (650) 463-5836
Fax. (650) 752-0202

Respectfully submitted,
DELTAGEN, INC.

Mariette A. Lapid
Mariette A. Lapid, Reg. No. 44,202

I certify that this amendment and enclosures are being deposited with the U. S. Postal Service with sufficient postage as first-class mail in an envelope addressed to The Commissioner for Patents, Washington, D.C. 20231, on October 22, 2001.

☐ also transmitted by facsimile.

Gayle D. Peterson
Gayle D. Peterson



Version with markings to show changes made

In the Claims:

Claims 31-39 have been amended as follows:

- ~~3421~~. A cell derived from the transgenic mouse of claim 17, claim 18, claim 19, or claim 20.
- ~~3222~~. A method of identifying an agent that ameliorates a phenotype associated with a disruption in a CX2 gene, the method comprising:
- (a) administering an agent to a transgenic mouse comprising a disruption in a CX2 gene; and
 - (b) determining whether the agent ameliorates at least one of the following phenotypes: : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3323~~. A method of identifying an agent which modulates CX2 expression, the method comprising:
- (a) administering an agent to the transgenic mouse comprising a disruption in a CX2 gene; and
 - (b) determining whether the agent modulates CX2 expression in the transgenic mouse, wherein the agent has an effect on at least one of the following: : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3424~~. A method of identifying an agent which modulates CX2 gene function, the method comprising:
- (a) providing a cell comprising a disruption in a CX2 gene;
 - (b) contacting the cell with an agent; and
 - (c) determining whether the agent modulates CX2 gene function, wherein the agent modulates a phenotype associated with a disruption in a CX2 gene.
- ~~3525~~. The method of claim ~~3524~~, wherein the phenotype comprises at least one of the following: increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.
- ~~3726~~. An agent identified by the method of claim ~~3222~~, claim ~~3323~~, claim ~~3424~~, or claim ~~3525~~.
- ~~3827~~. An agent that modulates the function, expression or activity of a CX2 gene.
- ~~3928~~. A method of ameliorating a condition associated with impaired glucose tolerance, the method comprising administering to a subject in need, a therapeutically effective amount of an agent that modulates CX2 function, expression or activity.